Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

White matter integrity and processing speed in sickle cell anemia.

Stotesbury H, Kirkham FJ, Kölbel M, Balfour P, Clayden JD, Sahota S, Sakaria S, Saunders DE, Howard J, Kesse-Adu R, Inusa B, Pelidis M, Chakravorty S, Rees DC, Awogbade M, Wilkey O, Layton M, Clark CA, Kawadler JM.

Neurology. 2018 Jun 5;90(23):e2042-e2050. doi: 10.1212/WNL.0000000000005644. Epub 2018 May 11.

2.

Proteomic analysis of plasma from children with sickle cell anemia and silent cerebral infarction.

Tewari S, Renney G, Brewin J, Gardner K, Kirkham F, Inusa B, Barrett JE, Menzel S, Thein SL, Ward M, Rees DC.

Haematologica. 2018 Mar 15. pii: haematol.2018.187815. doi: 10.3324/haematol.2018.187815. [Epub ahead of print]

3.

Overnight auto-adjusting continuous airway pressure + standard care compared with standard care alone in the prevention of morbidity in sickle cell disease phase II (POMS2b): study protocol for a randomised controlled trial.

Howard J, Slee AE, Skene S, Inusa B, Kawadler J, Downes M, Gavlak J, Koelbel M, Stotesbury H, Chorozoglou M, Tebbs S, Chakravorty S, Awogbade M, Rees DC, Gupta A, Murphy PB, Hart N, Sahota S, Nwosu C, Gwam M, Saunders D, Muthurangu V, Barber N, Ako E, Thein SL, Marshall M, Reading IC, Cheng MYE, Kirkham FJ, Liossi C.

Trials. 2018 Jan 22;19(1):55. doi: 10.1186/s13063-017-2419-0.

4.

How many people have sickle cell disease in the UK?

Dormandy E, James J, Inusa B, Rees D.

J Public Health (Oxf). 2017 Dec 27. doi: 10.1093/pubmed/fdx172. [Epub ahead of print]

PMID:
29294057
5.

Sickle Cell Disease.

Inusa B, Popoola J, Wonkam A.

N Engl J Med. 2017 Jul 20;377(3):302-303. doi: 10.1056/NEJMc1706325. No abstract available.

6.

European migration crises: The role of national hemoglobinopathy registries in improving patient access to care.

Inusa BPD, Colombatti R.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26515. Epub 2017 Mar 30. No abstract available.

PMID:
28371007
7.

Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.

Jakubowski JA, Hoppe CC, Zhou C, Smith BE, Brown PB, Heath LE, Inusa B, Rees DC, Small DS, Gupta N, Yao S, Heeney M, Kanter J.

Thromb Haemost. 2017 Feb 28;117(3):580-588. doi: 10.1160/TH16-09-0731. Epub 2016 Dec 8.

PMID:
27929203
8.

Associations between environmental factors and hospital admissions for sickle cell disease.

Piel FB, Tewari S, Brousse V, Analitis A, Font A, Menzel S, Chakravorty S, Thein SL, Inusa B, Telfer P, de Montalembert M, Fuller GW, Katsouyanni K, Rees DC.

Haematologica. 2017 Apr;102(4):666-675. doi: 10.3324/haematol.2016.154245. Epub 2016 Dec 1.

9.

Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke.

Dowling MM, Quinn CT, Ramaciotti C, Kanter J, Osunkwo I, Inusa B, Iyer R, Kwiatkowski JL, Johnson C, Rhodes M, Owen W, Strouse JJ, Panepinto JA, Neumayr L, Sarnaik S, Plumb PA, Dlamini N, Kirkham F, Hynan LS; PFAST Investigators.

Br J Haematol. 2017 Jan;176(2):300-308. doi: 10.1111/bjh.14391. Epub 2016 Oct 21.

10.

Proceedings of a Sickle Cell Disease Ontology workshop - Towards the first comprehensive ontology for Sickle Cell Disease.

Mulder N, Nembaware V, Adekile A, Anie KA, Inusa B, Brown B, Campbell A, Chinenere F, Chunda-Liyoka C, Derebail VK, Geard A, Ghedira K, Hamilton CM, Hanchard NA, Haendel M, Huggins W, Ibrahim M, Jupp S, Kamga KK, Knight-Madden J, Lopez-Sall P, Mbiyavanga M, Munube D, Nirenberg D, Nnodu O, Ofori-Acquah SF, Ohene-Frempong K, Opap KB, Panji S, Park M, Pule G, Royal C, Sangeda R, Tayo B, Treadwell M, Tshilolo L, Wonkam A.

Appl Transl Genom. 2016 Mar 15;9:23-9. doi: 10.1016/j.atg.2016.03.005. eCollection 2016 Jun.

11.

Sickle-Cell Disease in Nigerian Children: Parental Knowledge and Laboratory Results.

Obaro SK, Daniel Y, Lawson JO, Hsu WW, Dada J, Essen U, Ibrahim K, Akindele A, Brooks K, Olanipekun G, Ajose T, Stewart CE, Inusa BP.

Public Health Genomics. 2016;19(2):102-7. doi: 10.1159/000444475. Epub 2016 Mar 19.

PMID:
26991896
12.

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.

Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators.

N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8.

13.

Prevention of Morbidity in sickle cell disease--qualitative outcomes, pain and quality of life in a randomised cross-over pilot trial of overnight supplementary oxygen and auto-adjusting continuous positive airways pressure (POMS2a): study protocol for a randomised controlled trial.

Howard J, Inusa B, Liossi C, Jacob E, Murphy PB, Hart N, Gavlak J, Sahota S, Chorozoglou M, Nwosu C, Gwam M, Gupta A, Rees DC, Thein SL, Reading IC, Kirkham FJ, Cheng MY.

Trials. 2015 Aug 25;16:376. doi: 10.1186/s13063-015-0883-y.

14.

Hyperhemolysis in Patients With Hemoglobinopathies: A Single-Center Experience and Review of the Literature.

Danaee A, Inusa B, Howard J, Robinson S.

Transfus Med Rev. 2015 Oct;29(4):220-30. doi: 10.1016/j.tmrv.2015.06.001. Epub 2015 Jun 19. Review.

PMID:
26209603
15.

Juvenile polymyositis with unremitting pain and progressive loss of motor and bulbar function on a background of sickle cell disease.

Bali S, D'Cruz D, Lazaro M, Inusa BP.

BMJ Case Rep. 2015 Mar 27;2015. pii: bcr2014207579. doi: 10.1136/bcr-2014-207579.

16.

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.

De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, Rees DC, Heath PT, Telfer P, Driscoll C, Al Hajjar S, Tozzi A, Jiang Q, Emini EA, Gruber WC, Gurtman A, Scott DA.

Pediatr Blood Cancer. 2015 Aug;62(8):1427-36. doi: 10.1002/pbc.25502. Epub 2015 Mar 23.

PMID:
25810327
17.

Cerebral microhaemorrhages secondary to fat embolus syndrome in sickle cell disease.

Alobeidi F, Inusa BP, Singh RR, U-King-Im JM.

Postgrad Med J. 2015 Jan;91(1071):55-6. doi: 10.1136/postgradmedj-2014-132984. No abstract available.

PMID:
25583740
18.

Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.

Galadanci NA, Abdullahi SU, Tabari MA, Abubakar S, Belonwu R, Salihu A, Neville K, Kirkham F, Inusa B, Shyr Y, Phillips S, Kassim AA, Jordan LC, Aliyu MH, Covert BV, DeBaun MR.

Pediatr Blood Cancer. 2015 Mar;62(3):395-401. doi: 10.1002/pbc.25289. Epub 2014 Nov 14.

19.

Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy.

Beverung LM, Strouse JJ, Hulbert ML, Neville K, Liem RI, Inusa B, Fuh B, King A, Meier ER, Casella J, DeBaun MR, Panepinto JA; SIT trial investigators.

Am J Hematol. 2015 Feb;90(2):139-43. doi: 10.1002/ajh.23877.

20.

Subarachnoid haemorrhage and cerebral vasculopathy in a child with sickle cell anaemia.

Inusa B, Casale M, Booth C, Lucas S.

BMJ Case Rep. 2014 Oct 21;2014. pii: bcr2014205464. doi: 10.1136/bcr-2014-205464.

Supplemental Content

Support Center